Royalty Pharma revenue and financials
$56.44Change from previous close: −0.39%Absolute change: −$0.22
In the fiscal year ended December 2025, Royalty Pharma reported revenue of $2.38B (+5.06% year over year). Net income was $770.95M, a net margin of 32.4%.
Fiscal year ending in December. Sources and method on the page Methodology and sources.
At a glance
- Revenue growth
- +5.06%
- 2025 vs 2024
- Net income growth
- −10.25%
- 2025 vs 2024
- Net margin
- 32.4%
- 2024: 37.9%
Financial data
Amounts in millions of USD; per-share values in USD; shares in millions.
| Item | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total revenue | 674 | 631 | 622 | 609 | 579 | 568 | 594 | 565 | 537 | 568 | 596 | 536 |
| Cost of revenue | 268 | -197 | 23.1 | 12.1 | -204 | -127 | 164 | -228 | 212 | 584 | -76.5 | 277 |
| Gross profit | 406 | 828 | 599 | 597 | 783 | 695 | 430 | 792 | 325 | -15.6 | 673 | 259 |
| Selling, general and administrative | 162 | 159 | 194 | 118 | 165 | 111 | 67.6 | 56.7 | 54.7 | 57.7 | 59.2 | 57.2 |
| Research and development | 97.9 | 39.8 | 50.5 | 50.5 | 301 | 50.5 | 0.5 | 0.5 | 0.5 | 0.5 | 0.5 | 50.5 |
| Operating income | 133 | 632 | 359 | 428 | 225 | 534 | 362 | 735 | 270 | -73.8 | 613 | 151 |
| EBIT | 133 | 632 | 359 | 428 | 225 | 534 | 362 | 735 | 270 | -73.8 | 613 | 151 |
| EBITDA | 134 | 634 | 360 | 429 | 225 | — | — | — | — | — | 614 | 153 |
| Interest expense | 93.6 | 93.7 | 94.2 | 79.6 | 68.7 | 65.3 | 65.8 | 66.5 | 49.0 | 44.2 | 47.3 | 46.0 |
| Pre-tax income | 81.5 | 468 | 356 | 444 | 92.6 | 434 | 334 | 806 | 194 | -4.3 | 718 | 122 |
| Income tax | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | — | — | — | — | — | — | — |
| Net income | 17.9 | 295 | 214 | 288 | 32.2 | 239 | 208 | 544 | 102 | 4.8 | 494 | 72.1 |
| Net income to common shareholders | 17.9 | 295 | 214 | 288 | 32.2 | 239 | 208 | 544 | 102 | 4.8 | 494 | 72.1 |
| Basic EPS | 0.04 | 0.67 | 0.39 | 0.67 | 0.08 | 0.55 | 0.35 | 1.22 | 0.23 | 0.01 | 1.11 | 0.16 |
| Diluted EPS | 0.04 | 0.67 | 0.39 | 0.67 | 0.07 | 0.55 | 0.35 | 1.21 | 0.23 | 0.01 | 1.11 | 0.16 |
| Average shares (basic) | 445 | 437 | 556 | 432 | 424 | 435 | 589 | 448 | 451 | 449 | 446 | 448 |
| Average shares (diluted) | 557 | 557 | 556 | 560 | 562 | 578 | 589 | 593 | 597 | 597 | 597 | 601 |
| Dividend per share | 0.24 | 0.24 | 0.22 | 0.22 | 0.22 | 0.22 | 0.21 | 0.21 | 0.21 | 0.21 | 0.20 | 0.20 |